Rhenman & Partners Asset Management’s Haemonetics HAE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-10,047	Closed	-$354K	–	100
2014 Q2	$354K	Sell	10,047 -10,000	-50%	-$334K	0.11%	95
2014 Q1	$653K	Sell	20,047 -9,953	-33%	-$380K	0.2%	86
2013 Q4	$1.26M	Buy	+30,000	New	+$1.23M	0.49%	74

Other funds holding HAE

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Rhenman & Partners Asset Management's HAE Position: Q3 2014 in Review

Rhenman & Partners Asset Management sold out of Haemonetics (HAE) in Q3 2014, closing a stake of 10,047 shares — an estimated $354K sold.

Rhenman & Partners Asset Management first reported a position in HAE in Q4 2013 and held it in 3 quarters. The position peaked at $1.26M in Q4 2013. 170 funds tracked by Wall St. Rank hold HAE as of Q3 2014.

Rhenman & Partners Asset Management reported no remaining Haemonetics position as of Q3 2014 after selling out during the quarter.
Rhenman & Partners Asset Management sold 10,047 Haemonetics shares in Q3 2014, an estimated $354K.
Rhenman & Partners Asset Management first reported a position in Haemonetics in Q4 2013 and held it in 3 quarters.
Rhenman & Partners Asset Management's Haemonetics position peaked at $1.26M in Q4 2013.
170 funds tracked by Wall St. Rank held Haemonetics as of Q3 2014.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2014, filed 3 Nov 2014.